샘플 요청 목록

 카트 문의
시장보고서
상품코드
1577563

세계의 균상식육종 치료제 시장

Mycosis Fungoides Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 182 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

균상식육종 치료제 세계 시장, 2030년까지 5억 8,720만 달러에 달할 것으로 전망

2023년 4억 6,730만 달러로 추정되는 균상식육종 치료제 세계 시장은 2023-2030년 동안 연평균 3.3% 성장하여 2030년에는 5억 8,720만 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 저분자 의약품은 CAGR 3.5%를 기록하여 분석 기간 종료 시점에 3억 7,110만 달러에 도달할 것으로 예상됩니다. 생물학적 제제 부문의 성장률은 분석 기간 동안 CAGR 2.9%로 추정됩니다.

미국 시장 1억 2,730만 달러로 추정, 중국은 CAGR 6.4%로 성장 전망

미국의 균상식육종 치료제 시장은 2023년 1억 2,730만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2023-2030년 분석 기간 동안 6.4%의 CAGR을 기록하며 2030년까지 1억 2,120만 달러의 시장 규모에 도달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 1.0%와 2.5%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 연평균 1.8%의 성장률을 기록할 것으로 예상됩니다.

세계 균상식육종 치료제 시장 - 주요 동향 및 촉진요인 정리

균상식육종이란 무엇이며, 왜 효과적인 치료 관리가 중요한가?

균상식육종은 가장 흔한 유형의 피부 T 세포 림프종(CTCL)으로 주로 피부를 침범하는 림프구의 희귀 한 만성 암입니다. 이 질환은 피부에 침윤된 악성 T세포가 특징이며, 반점성 발진, 반점, 더 심해지면 종양과 전신 병변을 유발합니다. 균상식육종은 진행성 질환으로 수년까지 진행되어 초기 미진행 단계에서 환자의 삶의 질과 전체 생존기간에 큰 영향을 미치는 진행 단계로 넘어가기 때문에 효과적인 치료관리가 중요합니다. 이 질환은 일반적으로 완만하게 진행되는 질환이지만, 다양한 병태생리와 Sézary 증후군과 같은 공격적인 아형으로 변할 수 있기 때문에 피부 직접 치료와 전신 치료를 모두 고려한 종합적인 치료 접근이 필요합니다. 이 질환의 치료는 수십 년 동안 안정된 상태를 유지하는 환자도 있고, 빠르게 병이 진행되는 환자도 있어 그 이질성 때문에 복잡합니다. 따라서 만능 치료법은 존재하지 않으며, 병기, 증상의 중증도, 환자의 동반 질환에 따라 개인별 맞춤 치료 전략이 필요합니다. 균상식육종의 복잡성을 고려할 때, 환자의 예후를 개선하고 장기적인 질병 관리를 가능하게 하기 위해서는 보다 효과적이고 덜 침습적인 치료법을 연구하는 것이 가장 중요합니다.

균상식육종 치료의 현재 치료 접근법과 한계는 무엇인가?

균상식육종의 치료법은 다양하며, 병기와 병태에 따라 국소요법, 전신요법, 새로운 생물학적 제제 등 다양한 치료법이 있습니다. 초기 균상식육종에서는 코르티코스테로이드, 국소 화학요법제(예: 메클로레타민), 레티노이드(예: 벡사로텐)와 같은 피부 지시 요법이 국소 피부 병변의 관리와 증상 완화를 위해 자주 사용됩니다. 광선 요법, 특히 협대역 자외선 B(NB-UVB) 및 자외선 A(PUVA)와 같은 광선 요법은 초기 환자의 관해에 효과적임이 입증되었습니다. 더 진행된 환자의 경우, 인터페론, 보리노스타트와 같은 히스톤 탈아세틸화효소(HDAC) 억제제, 모겜리주맙과 같은 단클론항체와 같은 전신 요법이 광범위한 병변과 전신 병변을 대상으로 사용되고 있습니다. 이러한 치료 옵션이 있음에도 불구하고, 균상식육종은 재발하기 쉽고 시간이 지남에 따라 치료 저항성을 보일 수 있기 때문에 여전히 치료가 어려운 질환입니다. 치료와 관련된 부작용, 장기간의 방사선 치료로 인한 이차 암 발생 위험, 진행 단계에서의 제한된 효과 등 현재 치료법의 한계는 부작용이 적고 더 나은 제어를 제공할 수 있는 새로운 치료법의 필요성을 강조하고 있습니다. 이에 따라, 본 질환의 근본적인 분자 및 면역 기전을 표적으로 하는 새로운 치료법 탐색이 진행되고 있으며, 반응률 개선, 질병 진행 지연, 환자의 삶의 질 향상을 목표로 하는 새로운 치료법이 등장하고 있습니다.

기술 및 과학 혁신은 어떻게 정세를 변화시키고 있는가?

최근 분자생물학 및 면역치료의 발전은 균상식육종의 치료 환경을 변화시키고 있으며, 보다 표적화되고 효과적인 치료를 위한 새로운 길을 제공하고 있습니다. 가장 유망한 개발 분야 중 하나는 악성 T세포를 특이적으로 표적하도록 설계된 생물학적 제제의 사용으로, CCR4 수용체를 표적으로 하는 단클론항체인 모가무리주맙은 난치성 진균성 호흡곤란 환자에서 종양 부담을 줄이고 증상을 완화하는 데 탁월한 효능을 보였습니다. JAK-STAT 경로, PI3K 경로 등 T세포의 생존과 증식에 관여하는 주요 경로를 표적으로 하는 다른 생물학적 제제 및 저분자 화합물도 다양한 임상 개발 단계에 있습니다. 또한, 암세포에 대한 면역체계의 반응을 조절하는 체크포인트 억제제도 공격적인 CTCL 치료제로서의 가능성을 검토하고 있습니다. 유전자 및 분자 프로파일링을 통해 개인의 질병 특성에 맞는 맞춤형 치료를 제공하는 정밀의료의 등장은 치료에 혁명을 가져올 수 있는 또 다른 돌파구다. 치료에 대한 반응을 예측하는 특정 바이오마커를 식별하는 것은 치료 전략을 정교화하고 효과가 없는 약물에 불필요하게 노출되는 것을 최소화하는 데 도움이 될 수 있을 것으로 보입니다. 또한, 고해상도 PET/CT 스캔과 같은 첨단 영상 진단 기술은 질병 모니터링을 개선하여 임상의가 질병의 진행 징후를 조기에 발견하고 그에 따라 치료 계획을 조정할 수 있도록 돕고 있습니다. 이러한 기술 혁신은 균상호흡기질환의 치료 옵션을 넓힐 뿐만 아니라, 보다 개인화된 환자 중심의 치료로 가는 길을 열어주고 있습니다.

균상식육종 치료제 시장의 성장을 촉진하는 요인은 무엇인가?

균상식육종 치료제 시장의 성장은 주로 치료 기술의 발전, 임상 진료의 진화, 환자층의 변화에 영향을 받는 몇 가지 요인에 의해 주도되고 있습니다. 주요 요인 중 하나는 진균성 호흡육종 및 기타 피부 림프종의 유병률이 증가하고 있으며, 특히 이러한 질병에 걸리기 쉬운 노인 인구가 증가하고 있다는 점입니다. 노인 인구의 증가는 환자층을 크게 확대하여 효과적이고 내약성이 좋은 치료 옵션에 대한 수요를 촉진하고 있습니다. 또한, 조기 진단에 대한 관심이 높아지고 첨단 진단 도구의 도입으로 더 많은 환자를 조기에 발견할 수 있게 됨에 따라 조기 치료 개입의 필요성이 증가하고 있습니다. 또 다른 주요 요인은 연구개발 활동의 급증으로, 여러 제약사들이 진행성 균상식육종의 미충족 수요를 충족시키기 위해 새로운 생물학적 제제 및 표적치료제에 많은 투자를 하고 있다는 점입니다. 현재 진행 중인 개인 맞춤형 의료로의 전환은 임상의와 연구자들이 특정 질병 프로파일에 맞는 치료법을 개발하기 위해 노력하고 있기 때문에 시장 성장을 더욱 촉진하고 있습니다. 또한, 원격의료 및 디지털 헬스 플랫폼의 활용이 증가함에 따라 균상식육종과 같은 만성 질환의 모니터링 및 관리에 대한 수요가 증가하고 있는 것도 시장 확대에 기여하고 있습니다. 이러한 기술은 환자의 참여도를 높이고 장기적으로 질병을 보다 효과적으로 관리할 수 있기 때문입니다. 또한, 희귀질환 치료제에 대한 희귀의약품 지정 및 신속한 승인 경로와 같은 유리한 규제 프레임워크는 혁신적인 치료제의 개발 및 상용화를 촉진하고 있습니다. 이러한 요인들이 복합적으로 작용하여 균상호흡기질환 치료제 시장의 미래를 형성하고 있으며, 광범위한 암 및 피부과 영역에서 역동적이고 빠르게 진화하는 분야로 자리매김하고 있습니다.

조사 대상 기업 예시(주목받는 44개사)

  • 4SC
  • BioInvent International AB
  • Bristol-Myers Squibb Company
  • Cartherics Pty Ltd.
  • Citius Pharmaceuticals, Inc.
  • CRISPR Therapeutics
  • Helsinn Healthcare SA
  • Innate Pharma SA
  • Kite Pharma, Inc.
  • Kyowa Kirin Co., Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 24.10.30

Global Mycosis Fungoides Therapeutics Market to Reach US$587.2 Million by 2030

The global market for Mycosis Fungoides Therapeutics estimated at US$467.3 Million in the year 2023, is expected to reach US$587.2 Million by 2030, growing at a CAGR of 3.3% over the analysis period 2023-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$371.1 Million by the end of the analysis period. Growth in the Biologic Drugs segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$127.3 Million While China is Forecast to Grow at 6.4% CAGR

The Mycosis Fungoides Therapeutics market in the U.S. is estimated at US$127.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$121.2 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Mycosis Fungoides Therapeutics Market - Key Trends and Drivers Summarized

What Is Mycosis Fungoides and Why Is Effective Therapeutic Management Crucial?

Mycosis Fungoides is the most common type of cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer of the lymphocytes that primarily affects the skin. The disease is characterized by malignant T-cells infiltrating the skin, leading to patchy rashes, plaques, and in more severe stages, tumors and systemic involvement. Effective therapeutic management is critical because Mycosis Fungoides is a progressive disease that can evolve over several years, transitioning from early, less aggressive stages to more advanced stages where the disease can significantly impact the patient’s quality of life and overall survival. Although it is typically an indolent condition, its variable presentation and potential to transform into aggressive variants, such as Sézary syndrome, necessitate a comprehensive therapeutic approach that considers both skin-directed and systemic treatments. Managing this disease is complex due to its heterogeneity, with some patients remaining stable for decades while others experience rapid disease progression. As a result, there is no one-size-fits-all treatment, and the therapeutic strategy must be tailored to each individual, depending on the disease stage, severity of symptoms, and patient comorbidities. Given the complexity of Mycosis Fungoides, research into more effective, less invasive therapies continues to be of paramount importance to improve patient outcomes and provide long-term disease control.

What Are the Current Therapeutic Approaches and Limitations in Treating Mycosis Fungoides?

The treatment landscape for Mycosis Fungoides is diverse, encompassing a range of modalities that include topical therapies, systemic drugs, and newer biologics, depending on the stage and presentation of the disease. In early-stage Mycosis Fungoides, skin-directed therapies such as corticosteroids, topical chemotherapy agents (e.g., mechlorethamine), and retinoids (e.g., bexarotene) are commonly used to manage localized skin lesions and alleviate symptoms. Phototherapy, particularly narrowband ultraviolet B (NB-UVB) and psoralen plus ultraviolet A (PUVA), has shown to be effective in achieving remission in early-stage patients. For more advanced cases, systemic therapies, including interferons, histone deacetylase (HDAC) inhibitors like vorinostat, and monoclonal antibodies like mogamulizumab, are utilized to target widespread disease and systemic involvement. Despite the availability of these therapeutic options, Mycosis Fungoides remains a challenging condition to treat due to its relapsing nature and the potential for resistance to therapies over time. The limitations of current therapies, such as treatment-related side effects, risk of secondary cancers with long-term phototherapy, and limited efficacy in advanced stages, underscore the need for novel treatments that can provide better control with fewer adverse effects. As a result, the search for new therapies that target the underlying molecular and immune mechanisms of the disease is ongoing, with emerging treatments aiming to improve response rates, delay disease progression, and enhance patient quality of life.

How Are Technological and Scientific Innovations Changing the Mycosis Fungoides Therapeutics Landscape?

Recent advancements in molecular biology and immunotherapy are transforming the therapeutic landscape for Mycosis Fungoides, providing new avenues for more targeted and effective treatments. One of the most promising areas of development is the use of biologics, which are engineered to specifically target malignant T-cells. Mogamulizumab, a monoclonal antibody targeting the CCR4 receptor, has shown significant efficacy in reducing tumor burden and providing symptom relief in patients with refractory Mycosis Fungoides. Other biologics and small molecules targeting key pathways involved in T-cell survival and proliferation, such as the JAK-STAT and PI3K pathways, are also in various stages of clinical development. Additionally, checkpoint inhibitors, which modulate the immune system’s response to cancer cells, are being explored for their potential to treat aggressive forms of CTCL. The advent of precision medicine, which utilizes genetic and molecular profiling to tailor therapies to the individual’s unique disease characteristics, is another breakthrough that could revolutionize treatment. Identifying specific biomarkers that predict response to therapy could help refine treatment strategies and minimize unnecessary exposure to ineffective drugs. Furthermore, advanced imaging technologies, such as high-definition PET/CT scans, are improving disease monitoring, allowing clinicians to detect early signs of progression and adjust treatment plans accordingly. These innovations are not only expanding the therapeutic options for Mycosis Fungoides but are also paving the way for a more personalized, patient-centered approach to care.

What Factors Are Driving the Growth of the Mycosis Fungoides Therapeutics Market?

The growth in the Mycosis Fungoides therapeutics market is driven by several factors, primarily influenced by advancements in treatment technologies, evolving clinical practices, and changing patient demographics. One of the main drivers is the increasing prevalence of Mycosis Fungoides and other cutaneous lymphomas, particularly in the aging population, which is more susceptible to these conditions. The rise in the elderly population is significantly expanding the patient pool, driving the demand for effective and tolerable treatment options. Additionally, the growing focus on early diagnosis and the increased adoption of sophisticated diagnostic tools are leading to more patients being identified at earlier stages, thereby increasing the need for early-stage therapeutic interventions. Another key factor is the surge in research and development activities, with several pharmaceutical companies investing heavily in novel biologics and targeted therapies to address the unmet needs in advanced Mycosis Fungoides. The ongoing shift towards personalized medicine is further boosting market growth, as clinicians and researchers strive to match treatments with specific disease profiles. The increasing use of telemedicine and digital health platforms for monitoring and managing chronic conditions like Mycosis Fungoides is also contributing to market expansion, as these technologies enhance patient engagement and enable more effective long-term disease management. Furthermore, favorable regulatory frameworks, including orphan drug designations and expedited approval pathways for rare disease therapies, are incentivizing the development and commercialization of innovative therapeutics. Collectively, these factors are shaping the future of the Mycosis Fungoides therapeutics market, making it a dynamic and rapidly evolving segment within the broader oncology and dermatology space.

Select Competitors (Total 44 Featured) -

  • 4SC
  • BioInvent International AB
  • Bristol-Myers Squibb Company
  • Cartherics Pty Ltd.
  • Citius Pharmaceuticals, Inc.
  • CRISPR Therapeutics
  • Helsinn Healthcare SA
  • Innate Pharma SA
  • Kite Pharma, Inc.
  • Kyowa Kirin Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Mycosis Fungoides Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Mycosis Fungoides Drives Demand for Advanced Therapeutic Solutions
    • Here's the Story: How Growing Awareness and Early Diagnosis Expand the Addressable Market for Mycosis Fungoides Treatments
    • Increasing Focus on Targeted Therapies Propels Market Growth for Novel Drug Developments
    • Advancements in Immunotherapy and Monoclonal Antibodies Generate New Opportunities for Mycosis Fungoides Management
    • Here's How Personalized Medicine Approaches Strengthen the Business Case for Patient-Specific Treatment Protocols
    • Rising Adoption of Combination Therapies Spurs Demand for Multifaceted Treatment Regimens
    • Growing Focus on Minimally Invasive Treatment Options Drives Adoption of Topical and Skin-Directed Therapies
    • Growing Demand for Non-Chemotherapeutic Options Spurs Innovation in Biologic and Immune-Based Therapies
    • Rising Healthcare Expenditure in Emerging Markets Expands Market Scope for Mycosis Fungoides Therapeutics
    • Increasing Use of Digital Health Platforms Transforms Market Dynamics through Enhanced Patient Monitoring
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mycosis Fungoides Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small Molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Small Molecule Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biologic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biologic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Biologic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • JAPAN
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • CHINA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • EUROPE
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • FRANCE
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • GERMANY
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • INDIA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: India 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • AFRICA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제